On the Road to Individualizing Pharmacotherapy for Adolescents and Adults with Schizophrenia – Results from an Expert Consensus Following the Delphi Method

References

• Frangou S. Schizophrenia: more data, less debate. Schizophr Res. 2022;242:25–26. doi:10.1016/j.schres.2021.12.014
   PubMed Web of Science ®Google Scholar
• Carpiniello B, Pinna F, Manchia M, Tusconi M, Cavallaro R, Bosia M. Sustained symptomatic remission in schizophrenia: course and predictors from a two-year prospective study. Schizophr Res. 2022;239:34–41. doi:10.1016/j.schres.2021.11.023
   PubMed Web of Science ®Google Scholar
• Andreasen NC, Carpenter WT, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. AJP. 2005;162(3):441–449. doi:10.1176/appi.ajp.162.3.441
   Google Scholar
• Carbon M, Correll CU. Clinical Predictors of therapeutic response to antipsychotics in schizophrenia. Dialogues Clin Neurosci. 2014;16(4):505–524.
   PubMed Web of Science ®Google Scholar
• Solmi M, Cortese S, Vita G, et al. An umbrella review of candidate predictors of response, remission, recovery, and relapse across mental disorders. Mol Psychiatry. 2023;1–17. doi:10.1038/s41380-023-02298-3
   PubMed Web of Science ®Google Scholar
• Haro JM, Novick D, Suarez D, Alonso J, Lépine JP, Ratcliffe M. Remission and relapse in the outpatient care of schizophrenia: three-year results from the schizophrenia outpatient health outcomes study. J Clin Psychopharmacol. 2006;26(6):571. doi:10.1097/01.jcp.0000246215.49271.b8
   PubMed Web of Science ®Google Scholar
• McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30:67–76. doi:10.1093/epirev/mxn001
   PubMed Web of Science ®Google Scholar
• Moreno-Küstner B, Martín C, Pastor L. Prevalence of psychotic disorders and its association with methodological issues. a systematic review and meta-analyses. PLoS One. 2018;13(4):e0195687. doi:10.1371/journal.pone.0195687
   PubMed Web of Science ®Google Scholar
• Fusar-Poli P, McGorry PD, Kane JM. Improving outcomes of first-episode psychosis: an overview. World Psychiatry. 2017;16(3):251–265. doi:10.1002/wps.20446
   PubMed Web of Science ®Google Scholar
• Chong HY, Teoh SL, Wu DB-C, Kotirum S, Chiou C-F, Chaiyakunapruk N. Global economic burden of schizophrenia: a systematic review. Neuropsychiatr Dis Treat. 2016;12:357–373. doi:10.2147/NDT.S96649
   PubMed Web of Science ®Google Scholar
• Holm M, Taipale H, Tanskanen A, Tiihonen J, Mitterdorfer-Rutz E. Employment among people with schizophrenia or bipolar disorder: a population-based study using nationwide registers. Acta Psychiatr Scand. 2021;143(1):61–71. doi:10.1111/acps.13254
   PubMed Web of Science ®Google Scholar
• Jääskeläinen E, Juola P, Hirvonen N, et al. A systematic review and meta-analysis of recovery in schizophrenia. Schizophrenia Bulletin. 2013;39(6):1296–1306. doi:10.1093/schbul/sbs130
   PubMed Web of Science ®Google Scholar
• Hansen HG, Speyer H, Starzer M, et al. Clinical recovery among individuals with a first-episode schizophrenia an updated systematic review and meta-analysis. Schizophrenia Bulletin. 2023;49(2):297–308. doi:10.1093/schbul/sbac103
   PubMed Web of Science ®Google Scholar
• Kharawala S, Hastedt C, Podhorna J, Shukla H, Kappelhoff B, Harvey PD. The relationship between cognition and functioning in schizophrenia: a semi-systematic review. Schizophr Res. 2022;27:100217. doi:10.1016/j.scog.2021.100217
   Web of Science ®Google Scholar
• Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012;379(9831):2063–2071. doi:10.1016/S0140-6736(12)60239-6
   PubMed Web of Science ®Google Scholar
• Ostuzzi G, Bertolini F, Tedeschi F, et al. Oral and Long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants. World Psychiatry. 2022;21(2):295–307. doi:10.1002/wps.20972
   PubMed Web of Science ®Google Scholar
• Ostuzzi G, Vita G, Bertolini F, et al. Continuing, reducing, switching, or stopping antipsychotics in individuals with schizophrenia-spectrum disorders who are clinically stable: a systematic review and network meta-analysis. Lancet Psychiatry. 2022;9(8):614–624. doi:10.1016/S2215-0366(22)00158-4
   PubMed Web of Science ®Google Scholar
• Fountoulakis KN, Moeller H-J, Kasper S, et al. The report of the joint WPA/CINP workgroup on the use and usefulness of antipsychotic medication in the treatment of schizophrenia. CNS Spectrums. 2021;26(6):562–586. doi:10.1017/S1092852920001546
   Web of Science ®Google Scholar
• Correll CU, Rubio JM, Inczedy-Farkas G, Birnbaum ML, Kane JM, Leucht S. Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence. JAMA psychiatry. 2017;74(7):675–684. doi:10.1001/jamapsychiatry.2017.0624
   PubMed Web of Science ®Google Scholar
• Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative Efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939–951. doi:10.1016/S0140-6736(19)31135-3
   PubMed Web of Science ®Google Scholar
• Solmi M, Croatto G, Piva G, et al. Efficacy and acceptability of psychosocial interventions in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence. Mol Psychiatry. 2023;28(1):354–368. doi:10.1038/s41380-022-01727-z
   PubMed Web of Science ®Google Scholar
• Bighelli I, Rodolico A, García-Mieres H, et al. Psychosocial and psychological interventions for relapse prevention in schizophrenia: a systematic review and network meta-analysis. Lancet Psychiatry. 2021;8(11):969–980. doi:10.1016/S2215-0366(21)00243-1
   PubMed Web of Science ®Google Scholar
• Correll CU, Galling B, Pawar A, et al. Comparison of early intervention services vs treatment as usual for early-phase psychosis: a systematic review, meta-analysis, and meta-regression. JAMA psychiatry. 2018;75(6):555–565. doi:10.1001/jamapsychiatry.2018.0623
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Hagi K, Kurokawa S, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre–post studies. Lancet Psychiatry. 2021;8(5):387–404. doi:10.1016/S2215-0366(21)00039-0
   PubMed Web of Science ®Google Scholar
• Rosenheck R, Mueser KT, Sint K, et al. Supported employment and education in comprehensive, integrated care for first episode psychosis: effects on work, school, and disability income. Schizophr Res. 2017;182:120–128. doi:10.1016/j.schres.2016.09.024
   PubMed Web of Science ®Google Scholar
• Twamley EW, Vella L, Burton CZ, Becker DR, Bell MD, Jeste DV. The efficacy of supported employment for middle-aged and older people with schizophrenia. Schizophr Res. 2012;135(1):100–104. doi:10.1016/j.schres.2011.11.036
   PubMed Web of Science ®Google Scholar
• Precision Medicine Initiative. Available from: https://obamawhitehouse.archives.gov/precision-medicine. Accessed December 2, 2023.
   Google Scholar
• Mehta R, Jain RK, Badve S. Personalized Medicine: the Road Ahead. Clin Breast Cancer. 2011;11(1):20–26. doi:10.3816/CBC.2011.n.004
   PubMed Web of Science ®Google Scholar
• Ozomaro U, Wahlestedt C, Nemeroff CB. Personalized medicine in psychiatry: problems and promises. BMC Med. 2013;11:132. doi:10.1186/1741-7015-11-132
   PubMed Web of Science ®Google Scholar
• Giordano GM, Pezzella P, Perrottelli A, Galderisi S. Precision psychiatry’ needs to become part of ‘personalized psychiatry. Fortschr Neurol Psychiatr. 2020;88(12):767–772. doi:10.1055/a-1211-2826
   PubMed Web of Science ®Google Scholar
• Aryutova K, Stoyanov D. Pharmaco-magnetic resonance as a tool for monitoring the medication related effects in the brain may provide potential biomarkers for psychotic disorders. Int J Mol Sci. 2021;22(17):9309. doi:10.3390/ijms22179309
   PubMed Web of Science ®Google Scholar
• Aryutova K, Stoyanov DS, Kandilarova S, Todeva-Radneva A, Kostianev SS. Clinical use of neurophysiological biomarkers and self-assessment scales to predict and monitor treatment response for psychotic and affective disorders. Curr Pharm Des. 2021;27(39):4039–4048. doi:10.2174/1381612827666210406151447
   PubMed Web of Science ®Google Scholar
• Jiménez-Fernández S, Gurpegui M, Garrote-Rojas D, Gutiérrez-Rojas L, Carretero MD, Correll CU. Oxidative stress parameters and antioxidants in adults with unipolar or bipolar depression versus healthy controls: systematic review and meta-analysis. J Affect Disord. 2022;314:211–221. doi:10.1016/j.jad.2022.07.015
   PubMed Web of Science ®Google Scholar
• Schneider J, Bakštein E, Kolenič M, et al. Motor activity patterns can distinguish between interepisode bipolar disorder patients and healthy controls. CNS Spectr. 2022;27(1):82–92. doi:10.1017/S1092852920001777
   PubMed Web of Science ®Google Scholar
• Jiménez-Fernández S, Gurpegui M, Garrote-Rojas D, Gutiérrez-Rojas L, Carretero MD, Correll CU. Oxidative stress parameters and antioxidants in patients with bipolar disorder: results from a meta-analysis comparing patients, including stratification by polarity and euthymic status, with healthy controls. Bipolar Disord. 2021;23(2):117–129. doi:10.1111/bdi.12980
   PubMed Web of Science ®Google Scholar
• Huth F, Tozzi L, Marxen M, et al. Machine learning prediction of estimated risk for bipolar disorders using hippocampal subfield and amygdala nuclei volumes. Brain Sci. 2023;13(6):870. doi:10.3390/brainsci13060870
   PubMed Web of Science ®Google Scholar
• Voineskos AN, Hawco C, Neufeld NH, et al. Functional magnetic resonance imaging in schizophrenia: current evidence, methodological advances, limitations and future directions. World Psychiatry. 2024;23(1):26–51. doi:10.1002/wps.21159
   PubMed Web of Science ®Google Scholar
• McGorry P, Keshavan M, Goldstone S, et al. Biomarkers and clinical staging in psychiatry. World Psychiatry. 2014;13(3):211–223. doi:10.1002/wps.20144
   PubMed Web of Science ®Google Scholar
• Abi-Dargham A, Moeller SJ, Ali F, et al. Candidate biomarkers in psychiatric disorders: state of the field. World Psychiatry. 2023;22(2):236–262. doi:10.1002/wps.21078
   PubMed Web of Science ®Google Scholar
• Meehan AJ, Lewis SJ, Fazel S, et al. Clinical prediction models in psychiatry: a systematic review of two decades of progress and challenges. Mol Psychiatry. 2022;27(6):2700–2708. doi:10.1038/s41380-022-01528-4
   PubMed Web of Science ®Google Scholar
• Kahn RS, Sommer IE, Murray RM, et al. Schizophrenia. Nature Reviews Disease Primers. 2015;1(1):1–23. doi:10.1038/nrdp.2015.67
   Web of Science ®Google Scholar
• Kahn RS, Sommer IE, Murray RM, et al. Schizophrenia—an overview. JAMA Psychiatry. 2020;77(2):201–210. doi:10.1001/jamapsychiatry.2019.3360
   PubMed Web of Science ®Google Scholar
• Taipale H, Tanskanen A, Mehtälä J, Vattulainen P, Correll CU, Tiihonen J. 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). World Psychiatry. 2020;19(1):61–68. doi:10.1002/wps.20699
   PubMed Web of Science ®Google Scholar
• Kotov R, Jonas KG, Carpenter WT, et al. Validity and utility of hierarchical taxonomy of psychopathology (HiTOP): i. Psychosis Superspectrum. World Psychiatry. 2020;19(2):151–172. doi:10.1002/wps.20730
   PubMed Web of Science ®Google Scholar
• Winkelbeiner S, Leucht S, Kane JM, Homan P. Evaluation of differences in individual treatment response in schizophrenia spectrum disorders: a meta-analysis. JAMA Psychiatry. 2019;76(10):1063–1073. doi:10.1001/jamapsychiatry.2019.1530
   PubMed Web of Science ®Google Scholar
• Taipale H, Schneider-Thoma J, Pinzón-Espinosa J, et al. Representation and outcomes of individuals with schizophrenia seen in everyday practice who are ineligible for randomized clinical trials. JAMA Psychiatry. 2022;79(3):210–218. doi:10.1001/jamapsychiatry.2021.3990
   PubMed Web of Science ®Google Scholar
• McCutcheon RA, Pillinger T, Efthimiou O, et al. Reappraising the variability of effects of antipsychotic medication in schizophrenia: a meta-analysis. World Psychiatry. 2022;21(2):287–294. doi:10.1002/wps.20977
   PubMed Web of Science ®Google Scholar
• Dalkey N, Helmer O. An experimental application of the delphi method to the use of experts. Manage Sci. 1963;9(3):458–467.
   Web of Science ®Google Scholar
• Fink A, Kosecoff J, Chassin M, Brook RH. Consensus methods: characteristics and guidelines for use. Am J Public Health. 1984;74(9):979–983.
   PubMed Web of Science ®Google Scholar
• McKenna H, Keeney S, Hasson F. The Delphi Technique in Nursing and Health Research. Oxford: John Wiley & Sons, Inc.; 2011.
   Google Scholar
• Correll CU, Schooler NR. Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment. NDT. 2020;16:519–534. doi:10.2147/NDT.S225643
   Google Scholar
• Kirschner M, Aleman A, Kaiser S. Secondary negative symptoms - A review of mechanisms, assessment and treatment. Schizophr Res. 2017;186:29–38. doi:10.1016/j.schres.2016.05.003
   PubMed Web of Science ®Google Scholar
• Krause M, Zhu Y, Huhn M, et al. Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2018;268(7):625–639. doi:10.1007/s00406-018-0869-3
   PubMed Web of Science ®Google Scholar
• Galderisi S, Mucci A, Buchanan RW, Arango C. Negative symptoms of schizophrenia: new developments and unanswered research questions. Lancet Psychiatry. 2018;5(8):664–677. doi:10.1016/S2215-0366(18)30050-6
   PubMed Web of Science ®Google Scholar
• Helfer B, Samara MT, Huhn M, et al. Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-analysis. AJP. 2016;173(9):876–886. doi:10.1176/appi.ajp.2016.15081035
   Google Scholar
• Galling B, Vernon JA, Pagsberg AK, et al. Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia. Acta Psychiatrica Scandinavica. 2018;137(3):187–205.
   PubMed Web of Science ®Google Scholar
• Nielsen RE, Levander S, Kjaersdam Telléus G, Jensen SOW, Østergaard Christensen T, Leucht S. Second-generation antipsychotic effect on cognition in patients with schizophrenia—a meta-analysis of randomized clinical trials. Acta Psychiatrica Scandinavica. 2015;131(3):185–196. doi:10.1111/acps.12374
   PubMed Web of Science ®Google Scholar
• Carbon M, Correll CU. Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia. CNS Spectrums. 2014;19(S1):35–53. doi:10.1017/S1092852914000601
   Google Scholar
• Hagi K, Nosaka T, Dickinson D, et al. Association between cardiovascular risk factors and cognitive impairment in people with schizophrenia: a systematic review and meta-analysis. JAMA Psychiatry. 2021;78(5):510–518. doi:10.1001/jamapsychiatry.2021.0015
   PubMed Web of Science ®Google Scholar
• Taipale H, Solmi M, Lähteenvuo M, Tanskanen A, Correll CU, Tiihonen J. Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland. Lancet Psychiatry. 2021;8(10):883–891. doi:10.1016/S2215-0366(21)00241-8
   PubMed Web of Science ®Google Scholar
• Correll CU, Solmi M, Croatto G, et al. Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors. World Psychiatry. 2022;21(2):248–271. doi:10.1002/wps.20994
   PubMed Web of Science ®Google Scholar
• Chan JKN, Correll CU, Wong CSM, et al. Life expectancy and years of potential life lost in people with mental disorders: a systematic review and meta-analysis. eClinicalMedicine. 2023;65. doi:10.1016/j.eclinm.2023.102294
   Google Scholar
• Correll CU, Solmi M, Veronese N, et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry. 2017;16(2):163–180. doi:10.1002/WPS.20420
   PubMed Web of Science ®Google Scholar
• Correll CU, Detraux J, De Lepeleire J, De Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry. 2015;14(2):119–136. doi:10.1002/wps.20204
   PubMed Web of Science ®Google Scholar
• Correll CU, Bitter I, Hoti F, et al. Factors and their weight in reducing life expectancy in schizophrenia. Schizophr Res. 2022;250:67–75. doi:10.1016/j.schres.2022.10.019
   PubMed Web of Science ®Google Scholar
• Solmi M, Tiihonen J, Lähteenvuo M, Tanskanen A, Correll CU, Taipale H. Antipsychotics use is associated with greater adherence to cardiometabolic medications in patients with schizophrenia: results from a nationwide, within-subject design study. Schizophrenia Bulletin. 2022;48(1):166–175. doi:10.1093/schbul/sbab087
   PubMed Web of Science ®Google Scholar
• Correll CU. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry. 2010;25(Suppl 2):S12–21. doi:10.1016/S0924-9338(10)71701-6
   PubMed Web of Science ®Google Scholar
• Rubio JM, Taipale H, Tanskanen A, Correll CU, Kane JM, Tiihonen J. Long-term continuity of antipsychotic treatment for schizophrenia: a nationwide study. Schizophrenia Bulletin. 2021;47(6):1611–1620. doi:10.1093/schbul/sbab063
   PubMed Web of Science ®Google Scholar
• Solmi M, Radua J, Olivola M, et al. Age at onset of mental disorders worldwide: large-scale meta-analysis of 192 epidemiological studies. Mol Psychiatry. 2022;27(1):281–295. doi:10.1038/s41380-021-01161-7
   PubMed Web of Science ®Google Scholar
• Pringsheim T, Panagiotopoulos C, Davidson J, Ho J; CAMESA guideline group. Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth. J Can Acad Child Adolesc Psychiatry. 2011;20(3):218–233. PMID: 21804853; PMCID: PMC3143700.
   PubMedGoogle Scholar
• Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009;302(16):1765–1773. PMID: 19861668; PMCID: PMC3055794. doi:10.1001/jama.2009.1549
   PubMed Web of Science ®Google Scholar
• Correll CU, Penzner JB, Parikh UH, et al. Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child Adolesc Psychiatr Clin N Am. 2006;15(1):177–206. PMID: 16321730. doi:10.1016/j.chc.2005.08.007
   PubMed Web of Science ®Google Scholar
• Patton GC, Sawyer SM, Santelli JS, et al. Our future: a lancet commission on adolescent health and wellbeing. Lancet. 2016;387(10036):2423–2478. doi:10.1016/S0140-6736(16)00579-1
   PubMed Web of Science ®Google Scholar
• Tuomainen H, Schulze U, Warwick J, et al.; for the MILESTONE consortium. Managing the Link and Strengthening Transition from Child to Adult Mental Health Care in Europe (MILESTONE) background, rationale and methodology. BMC Psychiatry. 2018;18(1):167. doi:10.1186/s12888-018-1758-z
   PubMedGoogle Scholar
• Arango C, Buitelaar JK, Correll CU, et al. The transition from adolescence to adulthood in patients with schizophrenia: challenges, opportunities and recommendations. Eur. Neuropsychopharmacol. 2022;59:45–55. doi:10.1016/j.euroneuro.2022.04.005
   PubMed Web of Science ®Google Scholar
• Singh SP, Anderson B, Liabo K, Ganeshamoorthy T. Supporting young people in their transition to adults’ services: summary of NICE guidance. BMJ. 2016;353:2225. doi:10.1136/bmj.i2225
   Google Scholar
• Santosh P, Singh J, Adams L, et al. Validation of the Transition Readiness and Appropriateness Measure (TRAM) for the Managing the Link and Strengthening Transition from Child to Adult Mental Healthcare in Europe (MILESTONE) Study. BMJ Open. 2020;10(6):e033324. doi:10.1136/bmjopen-2019-033324
   PubMed Web of Science ®Google Scholar
• Dixon LB, Holoshitz Y, Nossel I. Treatment engagement of individuals experiencing mental illness: review and update. World Psychiatry. 2016;15(1):13–20. doi:10.1002/wps.20306
   PubMed Web of Science ®Google Scholar
• Galderisi S, Rossi A, Rocca P, et al. The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia. World Psychiatry. 2014;13(3):275–287. doi:10.1002/wps.20167
   PubMed Web of Science ®Google Scholar
• Strassnig MT, Raykov T, O’Gorman C, et al. Determinants of different aspects of everyday outcome in schizophrenia: the roles of negative symptoms, cognition, and functional capacity. Schizophr Res. 2015;165(1):76–82. doi:10.1016/j.schres.2015.03.033
   PubMed Web of Science ®Google Scholar
• Bowie CR, Depp C, McGrath JA, et al. Prediction of real-world functional disability in chronic mental disorders: a comparison of schizophrenia and bipolar disorder. AJP. 2010;167(9):1116–1124. doi:10.1176/appi.ajp.2010.09101406
   Google Scholar
• Harvey PD, Bosia M, Cavallaro R, et al. Cognitive dysfunction in schizophrenia: an expert group paper on the current state of the art. Schizophr Res. 2022;29:100249. doi:10.1016/j.scog.2022.100249
   Web of Science ®Google Scholar
• Correll CU, Schooler NR. Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment. Neuropsychiatr Dis Treat. 2020;16:519–534. doi:10.2147/NDT.S225643
   PubMed Web of Science ®Google Scholar
• Correll CU. Using patient-centered assessment in schizophrenia care: defining recovery and discussing concerns and preferences. J Clin Psychiatry. 2020;81(3):26418. doi:10.4088/JCP.MS19053BR2C
   Web of Science ®Google Scholar
• Harvey PD, Bellack AS. Toward a terminology for functional recovery in schizophrenia: is functional remission a viable concept? Schizophrenia Bulletin. 2009;35(2):300–306. doi:10.1093/schbul/sbn171
   PubMed Web of Science ®Google Scholar
• Shrivastava A, Johnston M, Shah N, Bureau Y. Redefining outcome measures in schizophrenia: integrating social and clinical parameters. Curr Opin Psychiatry. 2010;23(2):120. doi:10.1097/YCO.0b013e328336662e
   PubMed Web of Science ®Google Scholar
• Siafis S, Brandt L, McCutcheon RA, et al. Relapse in clinically stable adult patients with schizophrenia or schizoaffective disorder: evidence-based criteria derived by equipercentile linking and diagnostic test accuracy meta-analysis. Lancet Psychiatry. 2023;S2215(23):00364. doi:10.1016/S2215-0366(23)00364-4
   Google Scholar
• van Dijk F, de Wit I, Blankers M, Sommer I, de Haan L. The personal antipsychotic choice index. Pharmacopsychiatry. 2018;51(3):89–99. doi:10.1055/s-0043-116854
   PubMed Web of Science ®Google Scholar
• PAC Index. Available from: https://www.pakwijzer.nl/. Accessed December 2, 2023.
   Google Scholar
• Henshall C, Cipriani A, Ruvolo D, Macdonald O, Wolters L, Koychev I. Implementing a digital clinical decision support tool for side effects of antipsychotics: a focus group study. BMJ Ment Health. 2019;22(2):56–60. doi:10.1136/ebmental-2019-300086
   Google Scholar
• Pillinger T, Howes OD, Correll CU, et al. Antidepressant and antipsychotic side-effects and personalised prescribing: a systematic review and digital tool development. Lancet Psychiatry. 2023;10(11):860–876. doi:10.1016/S2215-0366(23)00262-6
   PubMed Web of Science ®Google Scholar
• SDMA APP. Available from: https://ebmpp.org/tools/sdma-app. Accessed December 2, 2023.
   Google Scholar
• Siafis S, Bursch N, Müller K, et al. Evidence-Based Shared-Decision-Making Assistant (SDM-Assistant) for choosing antipsychotics: protocol of a cluster-randomized trial in hospitalized patients with schizophrenia. BMC Psychiatry. 2022;22(1):406. doi:10.1186/s12888-022-04036-5
   PubMed Web of Science ®Google Scholar
• de Jong MH, Kamperman AM, Oorschot M, et al. Interventions to reduce compulsory psychiatric admissions: a systematic review and meta-analysis. JAMA Psychiatry. 2016;73(7):657–664. doi:10.1001/jamapsychiatry.2016.0501
   PubMed Web of Science ®Google Scholar
• Tinland A, Loubière S, Mougeot F, et al.; DAiP Group. Effect of psychiatric advance directives facilitated by peer workers on compulsory admission among people with mental illness: a randomized clinical trial. JAMA Psychiatry. 2022;79(8):752–759. doi:10.1001/jamapsychiatry.2022.1627
   PubMed Web of Science ®Google Scholar
• Fusar-Poli P, Manchia M, Koutsouleris N, et al. Ethical considerations for precision psychiatry: a roadmap for research and clinical practice. Eur Neuropsychopharmacol. 2022;63:17–34. doi:10.1016/j.euroneuro.2022.08.001
   PubMed Web of Science ®Google Scholar
• Salazar de Pablo G, Studerus E, Vaquerizo-Serrano J, et al. Implementing precision psychiatry: a systematic review of individualized prediction models for clinical practice. Schizophrenia Bulletin. 2021;47(2):284–297. doi:10.1093/schbul/sbaa120
   PubMed Web of Science ®Google Scholar
• Bhugra D, Tasman A, Pathare S, et al. The WPA-lancet psychiatry commission on the future of psychiatry. Lancet Psychiatry. 2017;4(10):775–818. doi:10.1016/S2215-0366(17)30333-4
   PubMed Web of Science ®Google Scholar
• Bergin AD, Vallejos EP, Davies EB, et al. Preventive digital mental health interventions for children and young people: a review of the design and reporting of research. NPJ Digit Med. 2020;3:133. doi:10.1038/s41746-020-00339-7
   PubMed Web of Science ®Google Scholar
• Torous J, Bucci S, Bell IH, et al. The growing field of digital psychiatry: current evidence and the future of apps, social media, chatbots, and virtual reality. World Psychiatry. 2021;20(3):318. doi:10.1002/WPS.20883
   PubMed Web of Science ®Google Scholar
• Guinart D, de Filippis R, Rosson S, et al. Development and validation of a computerized adaptive assessment tool for discrimination and measurement of psychotic symptoms. Schizophr Bull. 2021;47(3):644–652. doi:10.1093/schbul/sbaa168
   PubMed Web of Science ®Google Scholar
• Gibbons RD, Chattopadhyay I, Meltzer HY, Kane JM, Guinart D. Development of a computerized adaptive diagnostic screening tool for psychosis. Schizophr Res. 2022;245:116–121. doi:10.1016/j.schres.2021.03.020
   PubMed Web of Science ®Google Scholar
• Agulleiro LM, Patil B, Firth J, et al. A systematic review of digital interventions for smoking cessation in patients with serious mental illness. Psychological Medicine. 2023;53(11):4856–4868. doi:10.1017/S003329172300123X
   PubMedGoogle Scholar
• Sawyer C, McKeon G, Hassan L, et al. Digital health behaviour change interventions in severe mental illness: a systematic review. Psychological Medicine. 2023;1–41. doi:10.1017/S0033291723002064
   Web of Science ®Google Scholar
• Cochran JM, Fang H, Gallo CL, Peters-Strickland T, Lindenmayer J-P, Reuteman-Fowler JC. Participant engagement and symptom improvement: aripiprazole tablets with sensor for the treatment of schizophrenia. PPA. 2022;16:1805–1817. doi:10.2147/PPA.S362889
   Google Scholar
• Guinart D, Sobolev M, Patil B, Walsh M, Kane JM. A digital intervention using daily financial incentives to increase medication adherence in severe mental illness: single-arm longitudinal pilot study. JMIR Ment Health. 2022;9(10):e37184. doi:10.2196/37184
   PubMed Web of Science ®Google Scholar
• Guinart D, Marcy P, Hauser M, Dwyer M, Kane JM. Patient attitudes toward telepsychiatry during the COVID-19 pandemic: a nationwide, multisite survey. JMIR Ment Health. 2020;7(12):e24761. doi:10.2196/24761
   PubMed Web of Science ®Google Scholar
• Guinart D, Marcy P, Hauser M, Dwyer M, Kane JM. Mental health care providers’ attitudes toward telepsychiatry: a systemwide, multisite survey during the COVID-19 pandemic. PS. 2021;72(6):704–707. doi:10.1176/appi.ps.202000441
   Google Scholar
• Zhou J, Lamichhane B, Ben-Zeev D, Campbell A, Sano A. Predicting psychotic relapse in schizophrenia with mobile sensor data: routine cluster analysis. JMIR mHealth and uHealth. 2022;10(4):e31006. doi:10.2196/31006
   PubMed Web of Science ®Google Scholar
• Fulford KWM, Handa A. New resources for understanding patients’ values in the context of shared clinical decision-making. World Psychiatry. 2021;20(3):446–447. doi:10.1002/wps.20902
   PubMed Web of Science ®Google Scholar
• Guinart D, Kane JM, Correll CU. Is transcultural psychiatry possible? JAMA. 2019;322(22):2167–2168. doi:10.1001/jama.2019.17331
   PubMed Web of Science ®Google Scholar